97 related articles for article (PubMed ID: 21279929)
1. Psychopharmacology of aggression in schizophrenia.
Buckley P; Citrome L; Nichita C; Vitacco M
Schizophr Bull; 2011 Sep; 37(5):930-6. PubMed ID: 21860038
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Immune System with Pharmacotherapy in Schizophrenia.
Melbourne JK; Feiner B; Rosen C; Sharma RP
Curr Treat Options Psychiatry; 2017 Jun; 4(2):139-151. PubMed ID: 28674674
[No Abstract] [Full Text] [Related]
3. Cognitive Models of Positive and Negative Symptoms of Schizophrenia and Implications for Treatment.
Batinic B
Psychiatr Danub; 2019 Jun; 31(Suppl 2):181-184. PubMed ID: 31158119
[TBL] [Abstract][Full Text] [Related]
4. Current Concepts and Treatments of Schizophrenia.
Stępnicki P; Kondej M; Kaczor AA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30127324
[TBL] [Abstract][Full Text] [Related]
5. The Comparison of Olanzapine and Risperidone Treatment in Male Schizophrenic Patients using Positive and Negative Syndromes Scale (PANSS).
Lestari ET; Effendy E; Amin MM; Loebis B
Open Access Maced J Med Sci; 2018 Apr; 6(4):638-642. PubMed ID: 29731930
[TBL] [Abstract][Full Text] [Related]
6. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
Buckley PF; Stahl SM
Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
[TBL] [Abstract][Full Text] [Related]
8. Polypharmacy in schizophrenia.
Zink M; Englisch S; Meyer-Lindenberg A
Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
[TBL] [Abstract][Full Text] [Related]
9. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness.
Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A
J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy of schizophrenia: ploypharmacy approaches.
Rahiminejad F; Akhondzadeh S
Acta Med Iran; 2010; 48(4):203-8. PubMed ID: 21279929
[TBL] [Abstract][Full Text] [Related]
11. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.
Hellewell JS
J Clin Psychiatry; 1999; 60 Suppl 23():14-9. PubMed ID: 10625195
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
